Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment ...

For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...

Panelists discuss how advanced practice providers (APPs) implement effective monitoring strategies for patients with chronic myeloid leukemia (CML), including regular check-ins after starting new ...

Panelists discuss how advanced practice providers (APPs) serve as crucial touchpoints throughout the journey of patients with chronic myeloid leukemia (CML), offering more accessible communication, ...

Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma ...

Educating patients on the “risks and benefits” of clinical trials is a part of the pipeline for better treatment options in myeloproliferative neoplasms (MPNs) in which nurses can engage, said a nurse ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

The findings, which were presented at the 50th Annual Oncology Nursing Society Congress, showed that at a median follow-up of ...